Sunday, October 11, 2026

Week in Review 41/26

 



Welcome and thanks for reading!

In this review, I will make a summary of important and interesting news and events over the last week related to my portfolio holdings. Also, I will put together some interesting articles from other websites that caught my attention during the past week.



Received Dividends:



October 5, 2026


  • €12.66 - Kimberly-Clark Corporation (KMB)
  • €51.33 - The Coca-Cola Company (KO)
  • €34.82 - TELUS Corporation (TSE:T)
  • €101.45 - Canadian Natural Resources Limited (TSE:CNQ)


October 7 2026


  • €43.81 – JPM Global Equity Premium Income Active UCITS ETF (JGPI.DE)
  • €15.44 – JPM US Equity Premium Income Active UCITS ETF (JEIP.DE)
  • €82.32 – JPM Nasdaq Equity Premium Income Active UCITS ETF (JEQP.DE)


October 8, 2026


  • €25.49 - Best Buy Co., Inc. (BBY)


October 9, 2026


  • €128.70 - Altria Group, Inc. (MO)


Week 41 Total net dividends €496.02


Dividend income is reported after the deduction of taxes. Check more at my Monthly Dividend sheet.



Portfolio Holdings News:



October 5, 2026


  • NCC AB (NCC) to convert factory building to rental units in Turku; NCC and the Turku University Foundation have signed an agreement covering the conversion of the culturally historic Sanitas factory in Turku, into a modern rental housing complex. The conversion also includes a new extension. The order value is approximately SEK 180 million.


  • AbbVie Inc. (ABBV) said its third-quarter financial results will likely include $216 million in acquired in-process research and development (IPR&D) and milestone expenses on a pre-tax basis. As a result, both GAAP and non-GAAP diluted EPS are expected to be negatively impacted by $0.11 per share. Including the IPR&D and milestone expenses, AbbVie projects third-quarter adjusted diluted EPS of $3.73–$3.77 and full-year adjusted diluted EPS of $13.76–$13.96.


  • Lockheed Martin Corporation (LMT) announced that it won a $209M firm-fixed-price contract modification to produce AN/SLQ-32(V)6 electronic warfare systems for the U.S. Navy. The modification includes an option, which, if exercised, could lift the cumulative contract value to $1.71B.



October 6, 2026


  • Orion Corporation (ORION) announces agreement with Qilu Pharma Europe for pembrolizumab biosimilar for European market; ORION and Qilu Pharma Europe (“Qilu”) have entered into an agreement to commercialise intravenous (IV) pembrolizumab biosimilar in Europe. Pembrolizumab is an immune checkpoint inhibitor which is used to treat various cancers. Qilu is currently developing IV pembrolizumab. Under the terms of the agreement, ORION will gain exclusive right to distribute, market and sell Qilu’s IV pembrolizumab biosimilar in Europe. Qilu will supply the product to ORION, and is entitled to receive a share of profits from ORION as well as certain development, regulatory and sales milestone payments.





October 7, 2026


  • NCC AB (NCC) divests business area Industry for SEK 8.2 billion and strengthens focus on contracting; NCC has agreed to divest its Industry business area at an enterprise value of SEK 8.2 billion. The divestment will create a more focused NCC, specializing in contracting, while improving opportunities for long-term value creation. From NCC's perspective, it is a single transaction with two buyers: Heidelberg Materials and CRH. Heidelberg Materials is acquiring the operations in Sweden and Norway, while CRH is acquiring the operations in Denmark and Finland. The transaction is subject to approval by relevant authorities.



October 8, 2026


  • Viatris Inc. (VTRS) Agrees to Acquire Pacira BioSciences; VTRS and Pacira BioSciences (PCRX) said they entered into a definitive agreement under which VTRS will acquire all outstanding shares of Pacira for $36.50 per share in cash, representing an aggregate equity value of $1.65B. The transaction is expected to close by the end of 2026.


  • PepsiCo, Inc. (PEP) Reports Third-Quarter 2026 Results; PEP reported third-quarter non-GAAP EPS of $2.34, up 2% from the prior-year period and $0.04 above analyst expectations. Revenue increased 5.6% year over year to $25.27 billion, exceeding consensus estimates by $310 million. Looking ahead, management updated its fiscal 2026 guidance, now expecting core constant-currency EPS to grow approximately 5.04% year over year and net revenue to increase approximately 5.27% year over year.


  • RTX Corporation (RTX) announced that it won a new $4.43B noncompetitive, multi-year contract to manufacture and assemble Standard Missile-3 Block IB all-up rounds. The contract has a total potential value of $6.34B, including options.



October 9, 2026




Articles that caught my attention:





Thanks for stopping by!


No comments:

Post a Comment